{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:40:41Z","timestamp":1765827641833,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12032-017-1060-9","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T03:56:03Z","timestamp":1511236563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0563-4160","authenticated-orcid":false,"given":"Hideaki","family":"Miyake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1060_CR2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","volume":"50","author":"JM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick JM, Bellmunt J, Fizazi K, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014;50:1617\u201327.","journal-title":"Eur J Cancer"},{"key":"1060_CR3","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"1060_CR4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513\u201320.","journal-title":"N Engl J Med"},{"key":"1060_CR5","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/annonc\/mdv267","volume":"26","author":"K Chi","year":"2015","unstructured":"Chi K, Hotte SJ, Joshua AM, et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol. 2015;26:2044\u201356.","journal-title":"Ann Oncol"},{"key":"1060_CR6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"1060_CR7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"1060_CR8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"1060_CR9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"1060_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clgc.2016.06.010","volume":"15","author":"H Miyake","year":"2017","unstructured":"Miyake H, Hara T, Terakawa T, et al. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15:313\u20139.","journal-title":"Clin Genitourin Cancer"},{"key":"1060_CR11","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.clgc.2016.07.005","volume":"15","author":"H Miyake","year":"2017","unstructured":"Miyake H, Hara T, Ozono S, et al. Impact of prior use of an androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy on the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15:e217\u201322.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"1060_CR12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clgc.2016.12.015","volume":"15","author":"H Miyake","year":"2017","unstructured":"Miyake H, Hara T, Tamura K, et al. Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15(4):591\u20137.","journal-title":"Clin Genitourin Cancer"},{"key":"1060_CR13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1586\/14737140.2014.949677","volume":"14","author":"E Francini","year":"2014","unstructured":"Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014;14:1135\u201340.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1060_CR14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.eururo.2013.07.022","volume":"65","author":"JM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:1198\u2013204.","journal-title":"Eur Urol"},{"key":"1060_CR15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","volume":"67","author":"RJ Soest van","year":"2015","unstructured":"van Soest RJ, de Morr\u00e9e ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol. 2015;67:981\u20135.","journal-title":"Eur Urol"},{"key":"1060_CR16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","volume":"66","author":"MT Schweizer","year":"2014","unstructured":"Schweizer MT, Zhou XC, Wang H, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;66:646\u201352.","journal-title":"Eur Urol"},{"key":"1060_CR17","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943\u20137.","journal-title":"Ann Oncol"},{"key":"1060_CR18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/pros.22872","volume":"74","author":"AA Azad","year":"2014","unstructured":"Azad AA, Leibowitz-Amit R, Eigl BJ, et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014;74:1544\u201350.","journal-title":"Prostate"},{"key":"1060_CR19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","volume":"71","author":"JS Bono de","year":"2017","unstructured":"de Bono JS, Smith MR, Saad F, et al. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;71:656\u201364.","journal-title":"Eur Urol"},{"key":"1060_CR20","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.clgc.2014.03.010","volume":"12","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Harris A, Formaker C, et al. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014;12:e167\u201372.","journal-title":"Clin Genitourin Cancer"},{"key":"1060_CR21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"1060_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1060_CR23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/iju.13148","volume":"23","author":"S Parimi","year":"2016","unstructured":"Parimi S, Chi KN. Chemotherapy for metastatic castration-sensitive prostate cancer. Int J Urol. 2016;23:726\u201333.","journal-title":"Int J Urol"},{"key":"1060_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1704174\n                        \n                    .","journal-title":"N Engl J Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1060-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1060-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1060-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T09:15:34Z","timestamp":1511946934000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1060-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1060-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2017,11,21]]},"article-number":"200"}}